Vanlev omapatrilat: Completed Phase III trial

Bristol-Myers Squibb Co. (BMY), Princeton, N.J. Product: Vanlev omapatrilat Business: Cardiovascular Therapeutic category: Protease inhibitor, Vasodilation Target: Neutral endopeptidase and angiotens...